AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in this application:

1. (Currently Amended) A molecule comprising the antigen-binding portion of an isolated antibody which has an increased affinity for a fibroblast growth factor receptor 3 (FGFR3) and which blocks activation of said ~~fibroblast growth factor receptor~~FGFR3.

Claims 2-5. (Cancelled)

6. (Currently Amended) The molecule according to claim 1, wherein said molecule blocks constitutive activation of said FGFR3~~fibroblast growth factor receptor~~.

7. (Previously Presented) The molecule according to claim 6, comprising a V_H region and a V_L region, respectively, selected from SEQ ID NO: 96 and SEQ ID NO: 85; SEQ ID NO: 98 and SEQ ID NO: 87; and SEQ ID NO: 106 and SEQ ID NO: 95.

8. (Previously Presented) The molecule according to claim 6, comprising a V_H-CDR3 region and a V_L-CDR3 region, respectively, selected from SEQ ID NO: 8 and SEQ ID NO: 9; SEQ ID NO: 12 and SEQ ID NO:13; and SEQ ID NO: 24 and SEQ ID NO:25.

9. (Original) The molecule according to claim 8, comprising a V_H-CDR3 region and a V_L-CDR3 region having SEQ ID NO:24 and SEQ ID NO:25, respectively.

10. (Previously Presented) A pharmaceutical composition, comprising as an active ingredient at least one molecule according to claim 6 and a pharmaceutically acceptable carrier, excipient, or auxiliary agent.

Claims 11-14. (Cancelled)

15. (Currently Amended) A molecule according to claim 1 wherein said molecule ~~comprising the antigen-binding portion of an antibody which binds to a fibroblast growth factor receptor (FGFR) and which~~ blocks ligand-dependent activation of ~~the~~ said FGFR3.

Claims 16-17. (Cancelled)

18. (Previously Presented) The molecule according to claim 15, comprising a V_H region and a V_L region, respectively, selected from SEQ ID NO: 97 and SEQ ID NO: 86; SEQ ID NO: 99 and SEQ ID NO: 88; SEQ ID NO: 100 and SEQ ID NO: 89; SEQ ID NO: 101 and SEQ ID NO: 90; SEQ ID NO: 102 and SEQ ID NO: 91; SEQ ID NO: 103 and SEQ ID NO: 92; SEQ ID NO: 104 and SEQ ID NO: 93 and SEQ ID NO: 105 and SEQ ID NO: 94.

Claim 19. (Cancelled)

20. (Original) The molecule according to claim 15, comprising a V_H -CDR3 region and a V_L -CDR3 region selected from SEQ ID NO:10 and SEQ ID NO:11; SEQ ID NO:14 and SEQ ID NO:15; SEQ ID NO:16 and SEQ ID NO:17; SEQ ID NO:18 and SEQ ID NO:19; SEQ ID NO:20 and SEQ ID NO:21; SEQ ID NO:22 and SEQ ID NO:23; SEQ ID NO:26 and SEQ ID NO:27 and SEQ ID NO:28 and SEQ ID NO:29.

Claim 21. (Cancelled)

22. (Original) A pharmaceutical composition, comprising as an active ingredient at least one molecule according to claim 15 and a pharmaceutically acceptable carrier, excipient, or auxiliary agent.

Claims 23-30. (Cancelled)

31. (Currently Amended) A kit comprising the molecule of claim 1, ~~or a molecule comprising the antigen-binding portion of an antibody which binds to a fibroblast growth factor receptor (FGFR) and which blocks ligand-dependent activation of the FGFR, the kit further~~

~~comprising~~ at least one reagent suitable for detecting the presence of said molecule when bound to said FGFR3 ~~receptor protein tyrosine kinase~~ and instructions for use.

32. (Currently Amended, Withdrawn) A method for treating or inhibiting a skeletal dysplasia or a craniosynostosis disorder, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 10 to a subject in need thereof.~~, wherein the pharmaceutical composition is according to claim 10 or is a pharmaceutical composition comprising as an active ingredient at least one molecule that is an antigen-binding portion of an antibody which binds to a fibroblast growth factor receptor (FGFR) and which blocks ligand-dependent activation of the FGFR.~~

33. (Withdrawn) The method according to claim 32, wherein the skeletal dysplasia is selected from achondroplasia, thanatophoric dysplasia (TD), hypochondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) dysplasia.

34. (Withdrawn) The method according to claim 33, wherein said skeletal dysplasia is achondroplasia.

35. (Withdrawn) The method according to claim 32, wherein the craniosynostosis disorder is Muenke coronal craniosynostosis or Crouzon syndrome with acanthosis nigricans.

Claims 36-37. (Cancelled)

38. (Currently Amended, Withdrawn) A method for treating or inhibiting a cell proliferative disease or disorder associated with abnormal FGFR3 ~~RPTK~~ activity, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 10 to a subject in need thereof.~~, wherein the pharmaceutical composition is according to claim 10 or is a pharmaceutical composition comprising as an active ingredient at least one molecule that is an antigen-binding portion of an antibody which binds to a fibroblast growth factor receptor (FGFR) and which blocks ligand-dependent activation of the FGFR.~~

39. (Withdrawn) The method according to claim 38, wherein the cell proliferative disease or disorder is selected from solid tumors, non-solid cancer or tumor progression,

40. (Withdrawn) The method according to claim 39, wherein the tumor progression is the progression of transitional cell carcinoma, mammary carcinoma, osteosarcoma or chondrosarcoma.

41. (Withdrawn) The method according to claim 39, wherein the non-solid cancer is a hematopoietic malignancy.

42. (Withdrawn) The method according to claim 41, wherein the hematopoietic malignancy is multiple myeloma.

43. (Currently Amended, Withdrawn) The method according to claim 38, wherein the disorder is associated with the action of a constitutively activated receptor protein tyrosine kinase ~~or with ligand-dependent activation of a receptor protein tyrosine kinase~~.

44. (Currently Amended, Withdrawn) A method for screening a molecule comprising the antigen-binding portion of an antibody according to claim 1 ~~which blocks ligand-independent or ligand-dependent activation of a receptor protein tyrosine kinase~~, comprising: providing a library of antigen binding fragments; screening a library of antigen binding fragments for binding to a dimeric form of a FGFR3~~receptor protein tyrosine kinase~~; identifying an antigen binding fragment which binds to the dimeric form of the FGFR3~~receptor protein tyrosine kinase~~ as a candidate molecule for blocking ~~constitutive~~ activation of the FGFR3~~receptor protein tyrosine kinase~~; and determining whether the candidate molecule blocks constitutive and/or ligand-dependent activation of FGFR3 ~~the receptor protein tyrosine kinase~~ in a cell.

Claims 45-49. (Cancelled)